PPAR-α激动剂非诺贝特通过调节NOD小鼠Th1/Th17与Treg细胞反应改善干燥综合征样泪腺炎
研究在非肥胖糖尿病(NOD)小鼠干燥综合征干眼模型中,用含0.03%非诺贝特的饲料喂养8周,发现非诺贝特减轻泪腺淋巴细胞浸润、增加泪液分泌并减少角膜荧光素染色,同时降低Th1/Th17细胞比例、增加Treg细胞比例,并上调PPAR-α与LXR-β表达。作者认为非诺贝特可能通过激活PPAR-α/LXR-β信号调节Th1/Th17/Treg细胞反应,可能成为干燥综合征相关泪腺炎的新型治疗药物。
要点
- 0.03%非诺贝特饲料喂养NOD小鼠8周,减轻泪腺淋巴细胞浸润并增加泪液分泌。
- 非诺贝特降低Th1/Th17细胞比例、增加Treg细胞比例,并下调T-bet、IFN-γ、RORγt、IL-17表达。
- 非诺贝特上调PPAR-α与LXR-β的蛋白和mRNA表达,作者认为其可能成为干燥综合征相关泪腺炎的新型治疗药物。
核心结论
- 非诺贝特有效减轻自身免疫性干眼模型的泪腺炎症,该效应可能部分源于通过激活PPAR-α/LXR-β信号调节Th1/Th17/Treg细胞反应。
- 作者认为非诺贝特可能成为干燥综合征相关泪腺炎的新型治疗药物。
研究设计与样本
- 雄性非肥胖糖尿病(NOD)小鼠分别喂食含或不含0.03%非诺贝特的饲料8周。
- 通过评估泪液分泌、荧光素染色和苏木精-伊红染色确定临床评分。
- 用流式细胞术检测CD4+ T细胞内IFN-γ、IL-17和Foxp3,用实时PCR检测Th1、Th17和Treg细胞相关转录因子和细胞因子表达。
- 用实时PCR和Western blotting检测PPAR-α与肝X受体β(LXR-β)水平。
主要发现
- 非诺贝特有效减轻NOD小鼠泪腺淋巴细胞炎症、增加泪液分泌并减少角膜荧光素染色。
- 非诺贝特在体内和体外明显降低Th1和Th17细胞比例、增加Treg细胞比例。
- 非诺贝特降低泪腺中T-bet、IFN-γ、RORγt和IL-17表达,增加Foxp3和TGF-β1表达。
- 非诺贝特显著上调PPAR-α和LXR-β在蛋白和mRNA水平的表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effects and mechanisms of fenofibrate, a synthetic ligand of peroxisome proliferator-activated receptor α (PPAR-α), on autoimmune dacryoadenitis in a mouse model of Sjögren syndrome (SS) dry eye. METHODS: Male nonobese diabetic (NOD) mice were fed chow with or without 0.03% fenofibrate for 8 weeks, and clinical scores were determined by assessing tear secretion, fluorescein, and hematoxylin and eosin staining. Intracellular IFN-γ, IL-17, and Foxp3 in CD4+ T cells were measured by flow cytometry. The expressions of Th1, Th17, and Treg cell-related transcription factors and cytokines were detected by real-time PCR. The levels of PPAR-α and liver X receptor β (LXR-β) were detected with real-time PCR and Western blotting. RESULTS: Fenofibrate efficiently diminished the lymphocytic inflammation in lacrimal glands (LGs), increased tear secretion, and decreased corneal fluorescein staining in NOD mice. Meanwhile, treatment of fenofibrate evidently reduced the proportion of Th1 and Th17 cells and increased the proportion of Treg cells in vivo and vitro, together with decreased expression of T-bet, IFN-γ, RORγt, and IL-17, as well as increased expression of Foxp3 and TGF-β1 in LGs. Furthermore, fenofibrate significantly upregulated the expressions of PPAR-α and LXR-β at the protein and mRNA levels. CONCLUSIONS: Fenofibrate potently attenuated LG inflammation in a model of autoimmune dry eye, and this effect might partially result from regulating Th1/Th17/Treg cell responses by activating PPAR-α/LXR-β signaling. These data suggest that fenofibrate may be a novel class of therapeutic agent for SS-associated dacryoadenitis.
引用
- Guo X, Dang W, Li N, et al. PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice. Invest Ophthalmol Vis Sci. 2022. PMID: 35687344. doi:10.1167/iovs.63.6.12
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。